Added to YB: 2026-01-15
Pitch date: 2026-01-13
NVO [bullish]
Novo Nordisk A/S
-37.41%
current return
Author Info
Alpha Talon Investment Research is a Hong Kong–based private family office deploying only proprietary capital across biotech, value turnarounds, and catalyst-driven shorts, focused on intrinsic value, regulatory odds, and mispriced fundamentals. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 380.10
Price Target
1.2K (+387%)
Dividend
4.91%
EV/EBITDA
7.51
P/E
10.35
EV/Sales
3.77
Sector
Pharmaceuticals
Category
growth
Alpha Talon Investment Research Analysis of the 44th Annual J.P.Morgan Healthcare Conference - Novo Nordisk A/S
NVO: New CEO's strategic reset focuses tightly on diabetes/obesity core markets serving 2B+ patients w/ <10% penetration. Oral Wegovy + higher dose semaglutide launching 2026 to counter competition. Pipeline assets CagriSema/amycretin show >20% weight loss. $165-180 price target by 2030.
Read full article (5 min)